Developing Novel Apolipoprotein A-IV-Based Therapeutics for Type 2 Diabetes
Apofore is developing novel therapeutics for Type 2 diabetes based on the naturally occurring protein, Apolipoprotein A-IV (apo A-IV). The company’s approach is based on the discovery by its scientific founder Patrick Tso, PhD, at the University of Cincinnati, of apo A-IV as an important regulator of insulin secretion and glucose homeostasis. Recombinant apo A-IV, the company’s lead therapeutic, is in preclinical development. Apofore is a focused company funded by HealthCare Ventures.
Apolipoprotein A-IV Pharmacology in Type 2 Diabetes
Apofore’s therapeutic program for Type 2 diabetes is based on research in the laboratory of Patrick Tso at the University of Cincinnati demonstrating that Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion. Apo A-IV is a protein secreted by the small intestine in response to lipid absorption.
Contact Us
For more information about Apofore Corporation and apo A-IV contact: [email protected]